ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0036498;IRE1-mediated unfolded protein response;6.0;1.0;0.8231203125901445;9.628524252492122;55.46397693329154;5.825829909099042;0.0018563293936187412;0.6210535250702663;[ERN1, EXTL2, CTDSP2, EDEM1, LMNA, SYVN1]
GO:0060486;Clara cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;47.34738732320508;8.390779266560578;0.001584674443825551;0.7522251544931926;[NFIB]
GO:0030031;cell projection assembly;4.0;0.6729672293956388;0.5864836146978194;8.124446855715847;35.515967283127445;3.9749552523034066;0.0011886874626708887;0.45327939645711923;[BBS2, SPAG16, NCKAP1, ONECUT2, IFT122, EMP3, FNBP1L, DYNLL2, PARVG, RFX4, TMEM107, CCDC65, NCKAP1L, FXYD5, SNAP29, CLUAP1]
GO:0034198;cellular response to amino acid starvation;7.0;0.8653626801206646;0.7836007053175329;9.446202695698167;115.90251486529202;5.970411137910149;0.003879152867050031;0.6562464685024372;[BECN1, CDKN1A]
GO:0090331;negative regulation of platelet aggregation;10.0;0.9326813400603323;0.8815816818910864;9.601125278304007;548.6740902153413;7.379178354882098;0.01836362802488484;0.7926125360964777;[FGG, CD9]
GO:0032570;response to progesterone;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;105.99106082751567;6.166155715036245;0.0035474254201351726;0.6384578026126634;[OXTR, WBP2, THBS1]
GO:1901224;positive regulation of NIK/NF-kappaB signaling;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;238.82315740091596;5.572381008289503;0.007993196151321231;0.6599718239061428;[NLRP12, IL23A, SPHK1, ZFP91, LIMS1]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[MAP3K3, RRAS, SP1, TBXA2R, SPHK1, ITGB2, CIB1, EPHA1, THBS1]
GO:0071493;cellular response to UV-B;8.0;1.0;0.875;9.628524252492122;82.44278777713699;7.697632086000634;0.0027592859132088378;0.7686572628545723;[CDKN1A]
GO:0072583;clathrin-dependent endocytosis;7.0;0.8436909121759173;0.7727648213451592;9.223059144383958;30.046907922432062;6.558197802812269;0.0010056429677022863;0.6863059058804069;[CLTA, FNBP1L]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[ERN1, KARS, PDE6H, THBS1]
GO:0030823;regulation of cGMP metabolic process;9.0;0.7586651285174919;0.775573189439035;9.392135474427892;212.55514157362143;6.444869117505266;0.00711402930126111;0.7258315315665724;[ADNP, THBS1]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[CDKN1C, USP36, CIITA, BTG2, NAB1, GFI1, GMNN, ARID4A, OTUD7B, IKZF2, YY1, FLCN, NIPBL, SAP130, DPF2, TRIM24, WWC3, EP300, SOX8, LRRFIP1, ZNF564, DACT1, TLE4, ZNF485, TSC22D4, PEG3, ZNF282, RUNX2, SIRT2, EID1, ILF3, SFRP1, ZNF93, TFDP2, MTF2, HOXB4, TIMELESS, LCOR, HDAC3, ZNF350, HDAC1, MAX, FOXG1, LRP8, SUPT6H, ARNTL, RXRA, BAG3, TPR, HIVEP1, SUDS3, E2F7, ZNF189, E2F8, IRX1, TFAP2A, DR1, CREBBP, UBE2I, NFYC, H3F3A, PER2, CENPF, GFI1B, HIST3H2A, CNOT1, NFIB, NFIC, PKIA, SP3, ZNF658, TAF7, EZH2, LIMS1]
GO:0071375;cellular response to peptide hormone stimulus;7.0;0.7369933605727446;0.7194160455435727;9.117698628726131;386.0268190343683;4.727217620430932;0.012919970231498398;0.5926694942041391;[ERRFI1, SP1, MAX, CRHR1, TSHR, RAB8B]
GO:2000353;positive regulation of endothelial cell apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;129.82178199018807;6.943860283624253;0.00434501821119318;0.7513499630073597;[THBS1]
GO:0019369;arachidonic acid metabolic process;9.0;0.8653626801206646;0.8289219652406215;9.474373572664863;252.17630471420017;5.769740442447999;0.008440113974844485;0.6913054197274496;[DAGLB, MGLL]
GO:0051402;neuron apoptotic process;5.0;0.8259837884571596;0.7032329060895001;9.022388448921806;23.44398779513952;6.113511981550823;7.846491732841165E-4;0.6028862989048107;[POLB, DIABLO, MAX]
GO:0065003;protein-containing complex assembly;4.0;0.45485133202666184;0.4774256660133309;6.058991556010752;36.471478728154885;2.4440506132939883;0.0012206675708314864;0.3749888620238313;[AHCTF1, NDUFA11, NDUFA10, GMNN, CLTA, PKD2L1, USP39, TMEM141, CLYBL, PSMD8, CHAF1A, NUP62, TMED2, EP300, OIP5, FBXO5, SNAP29, RBM5, TLE4, ATPAF2, FGA, PDCD6IP, TBP, ATPIF1, FGG, MED6, TAPBP, DDB1, COX7A2L, ALDH5A1, NDUFS7, KCTD10, TRAPPC6B, NDUFS6, SNRPG, POLR1E, VAMP4, TSPYL6, CHMP6, ALDOA, SLU7, MCM2, COLEC12, NDUFB7, HIST1H2BO, NDUFB10, HIST1H2BJ, TUBGCP2, HDAC1, YTHDC1, EPB41, MAX, HSD17B8, TM9SF4, NAPG, ATXN2, HLA-DMA, SPAST, RXRA, TSPAN4, NCKAP1L, ECT2, TRAPPC2, TRAPPC3, CREBBP, RRM1, NDUFA7, CPSF6, H3F3A, NUP153, RPL3L, SETX, VIL1, CENPF, COL1A2, SYNJ1, ARPC2, TAF7, CCDC65, CENPP, SEC24C]
GO:0090343;positive regulation of cell aging;5.0;0.8653626801206646;0.7229223519212526;9.34084218004034;80.4288724658014;7.379178354882098;0.0026918819801445447;0.6676125360964777;[LMNA]
GO:0007265;Ras protein signal transduction;7.0;0.7586651285174919;0.7302519295159464;8.935377071932177;27.526979089716047;4.2636448815154875;9.213032174599934E-4;0.5689623627776663;[RAB3B, NCKAP1, CDKN1A, KSR1, RAB27B, RAB21, RAB43, RHOT1, COL1A2, ALS2, RRAS, RAB18, ELMO1, TAX1BP3, KPNB1, RAB8B]
GO:0045652;regulation of megakaryocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;68.9575807315309;5.845247994956144;0.0023079481692908138;0.6498456195510879;[HDAC1, H3F3A, EP300, CIB1, THBS1]
GO:0007266;Rho protein signal transduction;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;29.60642063139588;5.334422371190153;9.9090025448413E-4;0.6478026081386739;[RHOT1, COL1A2, TAX1BP3]
GO:1900026;positive regulation of substrate adhesion-dependent cell spreading;8.0;1.0;0.875;9.628524252492122;350.51777089970517;6.280566066213989;0.011731514346499779;0.6961884407023742;[FGA, ARPC2, FGG, CIB1, UNC13D, LIMS1]
GO:0051895;negative regulation of focal adhesion assembly;8.0;1.0;0.875;9.628524252492122;270.76229412472316;7.069023426578259;0.009062170314110184;0.7365101867784198;[THBS1]
GO:0051412;response to corticosterone;8.0;0.9326813400603323;0.8413406700301662;9.55953138100517;159.4387911184404;6.7325511899570465;0.0053362728531380675;0.719302980950052;[CDKN1A]
GO:0048010;vascular endothelial growth factor receptor signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.186691500213083;31.002284443533863;5.572381008289503;0.0010376185600805164;0.6599718239061428;[NCKAP1, ITGB3, ELMO1, NCKAP1L]
GO:0071480;cellular response to gamma radiation;7.0;1.0;0.8509193652572005;9.628524252492122;60.39874674087868;6.444869117505266;0.0020214916980741903;0.6805102716434839;[CDKN1A, ELK1]
GO:2000009;negative regulation of protein localization to cell surface;7.0;1.0;0.8509193652572005;9.628524252492122;73.78875676133134;7.212124270218933;0.0024696432832320894;0.7197477358342742;[TAX1BP3]
GO:0051894;positive regulation of focal adhesion assembly;8.0;1.0;0.875;9.628524252492122;280.4986055833795;6.599019797332524;0.009388035896519984;0.712474179321389;[SFRP1, LIMS1]
GO:0071363;cellular response to growth factor stimulus;5.0;0.7671156992804218;0.6737988615011312;8.935377071932177;60.394260804020476;4.247644540169047;0.0020213415578046274;0.5074657511808371;[TBX1, BECN1, ERRFI1, CIB1, LRP8, THBS1, RUNX2, SIRT2, SETX, ERN1, VIL1, SFRP1, ATP7A, LIMS1]
GO:0006606;protein import into nucleus;9.0;0.8933024483968273;0.8428918493787028;9.551563211355994;277.5355368998559;5.288437257948329;0.009288864654271135;0.6666915524892495;[NUP62, LMNA, NUP153, TNPO2, KPNB1]
GO:2000124;regulation of endocannabinoid signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;44.98673222696701;9.083926447120524;0.001505665442206118;0.8154717862087246;[MGLL]
GO:0034059;response to anoxia;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;21.16160540946;8.67846133901236;7.082598888462125E-4;0.7340579283277371;[OXTR]
GO:0031100;animal organ regeneration;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;28.087648497102798;5.420364800990877;9.400683179555208E-4;0.5271977079954144;[UPF2, CDKN1A, LCP1, RPL19, EZH2]
GO:0018149;peptide cross-linking;7.0;0.6007507099811141;0.6512947202477576;8.117066748418225;151.15475272427284;5.69953618377475;0.005059013543235805;0.6423939107509793;[TGM6, THBS1]
GO:0034976;response to endoplasmic reticulum stress;4.0;0.6799073451904818;0.5899536725952409;8.284789505791027;28.997869804256865;4.300610075748959;9.705326059599744E-4;0.4699333992726228;[EDEM1, SYVN1, DERL2, ERLIN2, THBS1, BBC3, ERN1, CREB3, EXTL2, TBL2, CTDSP2, LMNA, UBQLN1, MAN1B1]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[IGFBP5, THBS1]
GO:0031581;hemidesmosome assembly;6.0;1.0;0.8231203125901445;9.628524252492122;36.796901128588246;7.292166977892469;0.0012315591657128446;0.6960420709600095;[CD151]
GO:0006260;DNA replication;7.0;0.7307253602413294;0.7162820453778652;9.271849308553389;254.20053156235352;4.77312732173501;0.008507863025766288;0.5950173184638491;[POLB, UPF1, RRM1, FEN1, CHAF1A, NCOA6, NFIB, NFIC, CDK2AP1, WRNIP1, MCM2]
GO:0006261;DNA-dependent DNA replication;8.0;0.7586651285174919;0.754332564258746;9.318369324188282;254.89367874291247;6.250713103064308;0.008531062038107634;0.6946617587785947;[POLB, CDK2AP1, WRNIP1]
GO:0048812;neuron projection morphogenesis;7.0;0.6547035408479693;0.6782711356811852;8.502512989635898;62.99970935475633;4.360973225476049;0.002108543576046295;0.5739397388140403;[UGT8, NCKAP1, C12orf57, SLC9A6, ALS2, NFIB, NCKAP1L, NPTX1, ATP7A, TRAK1, PAFAH1B1, ZNF365]
GO:0007595;lactation;6.0;1.0;0.8231203125901445;9.628524252492122;25.956233089099676;5.9928839937622085;8.687317623989867E-4;0.6295966787287501;[OXTR, ATP7A, USF2]
GO:0002581;negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II;6.0;0.8653626801206646;0.7558016526504768;9.427853557029971;55.710237364246;8.67846133901236;0.0018645715086227877;0.7669372290569613;[THBS1]
GO:0038096;Fc-gamma receptor signaling pathway involved in phagocytosis;10.0;1.0;0.9152410118609203;9.628524252492122;384.64074149301706;4.886724499458715;0.01287357946357817;0.6651483300191682;[NCKAP1, ARPC2, WIPF2, ELMO1, NCKAP1L]
GO:0009414;response to water deprivation;5.0;0.8436909121759173;0.712086467948879;9.427853557029971;59.73918226934355;7.697632086000634;0.001999416668781396;0.6838982747154925;[CD9]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[FGA, SERPINA3, ITGB3, FGG, CD9, RAB27B, CALM1, ALDOA, A2M, THBS1]
GO:0034605;cellular response to heat;5.0;0.8436909121759173;0.712086467948879;9.260799472366804;50.43140892920004;5.666199763507158;0.0016878938715389536;0.5800107312719123;[CDKN1A, BAG3, TPR, TFEC, SLU7, IER5, THBS1]
GO:0010757;negative regulation of plasminogen activation;10.0;1.0;0.9152410118609203;9.628524252492122;820.5340776865997;7.9853141584524145;0.027462537147443688;0.8236103492792612;[THBS1]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[CIITA, CDKN1A, ITGB2, IL5RA, CIB1, RORA, LRP8, IL21R, NCAM1, CCR2, IFNAR2, BBS2, MAP3K3, IL4R, CCL20, FLT3LG, YWHAZ, CD4, COL1A2, KARS, IL23A, SDC1, PSME2, LCP1, LIMS1]
GO:0048146;positive regulation of fibroblast proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.74573076450893;5.825829909099042;0.0021335122412550348;0.6210535250702663;[CDKN1A, SPHK1, FNTB]
GO:0010759;positive regulation of macrophage chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;998.0472698001994;7.292166977892469;0.033403743935984914;0.7881627702307852;[KARS, THBS1]
GO:0010754;negative regulation of cGMP-mediated signaling;8.0;1.0;0.875;9.628524252492122;239.1998693179246;9.777073627680469;0.008005804360164796;0.875;[THBS1]
GO:2000379;positive regulation of reactive oxygen species metabolic process;6.0;0.7763722522362496;0.7113064387082693;9.253830803050711;112.71770282919289;5.299736813202263;0.0037725600743465397;0.5941490996802742;[CDKN1A, ITGB2, PTX3, THBS1]
GO:0010751;negative regulation of nitric oxide mediated signal transduction;8.0;1.0;0.875;9.628524252492122;239.1998693179246;8.67846133901236;0.008005804360164796;0.8188169164668168;[THBS1]
GO:0090201;negative regulation of release of cytochrome c from mitochondria;9.0;1.0;0.896240625180289;9.628524252492122;472.8116675549172;6.943860283624253;0.015824581010188264;0.7513499630073597;[LMNA]
GO:0002227;innate immune response in mucosa;5.0;1.0;0.7902410118609202;9.628524252492122;46.05095502005584;6.832634648514029;0.0015412840213524692;0.639662265535933;[HIST1H2BJ, DEFB1, RNASE3]
GO:0030913;paranodal junction assembly;6.0;1.0;0.8231203125901445;9.628524252492122;88.99224575364705;7.8311634786251565;0.00297849037755313;0.7236063770733796;[UGT8, CD9]
GO:0001934;positive regulation of protein phosphorylation;9.0;0.5833093054345528;0.6878952778975655;8.604019935977734;663.1129447749842;2.9039097934679514;0.02219379349871355;0.5447467070638558;[CDKN1A, HDAC3, ITGB3, CIB1, LRP8, THBS1, FLCN, DVL3, NCKAP1L, ECT2, MARK2, TBX1, MAP3K3, FGA, FBXO18, KSR1, PDE6H, CCL20, SPHK1, FGG, ZFP91, FLT3LG, SENP2, GFRA2, ERN1, CDK9, CD4, KARS, ALS2, IL23A, JTB, CDK2AP1, CAMK1, ADNP, CALM1, EPHA1, CALM2, ARHGEF5, EZH2]
GO:2001237;negative regulation of extrinsic apoptotic signaling pathway;9.0;0.8436909121759173;0.8180860812682478;9.50592193039979;358.6811287979994;5.152100814396198;0.012004734588810557;0.6597193004257005;[FGA, FGG, LMNA, RFFL, THBS1]
GO:0010763;positive regulation of fibroblast migration;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;201.49065414776382;7.379178354882098;0.006743710864509851;0.7523715242355574;[THBS1]
GO:0007050;cell cycle arrest;6.0;0.811012628672052;0.7286266269261705;9.292052015870908;55.61614271062087;4.7664383335842135;0.0018614222452456451;0.5668761906316916;[ERN1, CDKN1C, CDKN1A, TP53INP1, PRR11, THBS1, PPM1G]
GO:0040037;negative regulation of fibroblast growth factor receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;298.26786127592857;7.004484905440688;0.00998275689325772;0.7091290490632969;[THBS1]
GO:0045727;positive regulation of translation;8.0;0.6634067003016617;0.7067033501508309;9.123968241739727;1032.6861465930526;5.104244793218563;0.03456307596927652;0.6360313160968547;[RPS9, RXRA, ITGA2, POLR2G, THBS1]
GO:0006886;intracellular protein transport;8.0;0.5537205960740763;0.6518602980370382;8.117066748418225;90.55259897265384;3.0436717358431102;0.0030307139955665606;0.5306535141162272;[RAB3B, TRAM1, AHCYL1, CLTA, RAB43, NUP62, TMED2, TMED1, EVI5L, TNPO2, TBC1D22A, RAB8B, VPS18, GSTK1, TMED9, RPS9, SSR2, COG3, BCR, ACOX2, AGPS, SLU7, KPNB1, ACOT4, RABGAP1, HSD17B4, ZDHHC24, DERL2, VPS26B, TRAK1, NAPG, ARNTL, RAB21, AP3M1, LMNA, VPS11, RPL19, VPS16, PEX16, PEX19, SYVN1, NUP153, RAB27B, ARCN1, PAN3, SNX17, VPS41, RAB18, SEC24C]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[ERRFI1, RABGAP1, DOCK8, RIC8A, ABR, DOCK11, ARHGAP21, RGS1, DVL3, NCKAP1L, EVI5L, ECT2, A2M, TBC1D22A, CCL20, ARHGAP25, BCR, DEPDC1B, SFRP1, ALS2, GNAQ, PKP4, TAX1BP3, DOCK2, EPHA1, ARHGEF5, EZH2, LIMS1]
GO:0001992;regulation of systemic arterial blood pressure by vasopressin;7.0;1.0;0.8509193652572005;9.628524252492122;25.380868944193306;8.16763571524637;8.494748422630829E-4;0.7686126355688037;[OXTR]
GO:0060689;cell differentiation involved in salivary gland development;4.0;0.8436909121759173;0.6718454560879586;9.158520623246385;21.066225782797595;9.083926447120524;7.050676185779127E-4;0.714552420951524;[NFIB]
GO:0030866;cortical actin cytoskeleton organization;6.0;0.7671156992804218;0.7066781622303554;9.117698628726131;53.946853691669205;6.088194173566533;0.0018055526440439148;0.63447084575632;[VIL1, NCKAP1, PDCD6IP, EPB41, WIPF2, NCKAP1L]
GO:2000278;regulation of DNA biosynthetic process;7.0;0.6913464685778243;0.6965925995461126;9.040737587590003;150.73814970462044;5.152100814396198;0.005045070215086414;0.6143980405026119;[CDKN1A, GNL3L, SMG5, DCP2]
GO:0051968;positive regulation of synaptic transmission, glutamatergic;8.0;0.8933024483968273;0.8216512241984136;9.55953138100517;135.83014596643335;6.375876246018314;0.004546112746301595;0.701062607729944;[OXTR]
GO:0033574;response to testosterone;5.0;0.9326813400603323;0.7565816818910864;9.533214072687796;91.03892825708995;6.063501560976162;0.003046990999048697;0.6003287636709002;[TBXA2R, ELK1, THBS1]
GO:0071456;cellular response to hypoxia;6.0;1.0;0.8231203125901445;9.628524252492122;103.24589989147204;5.104244793218563;0.0034555473540902374;0.5841516286869992;[NPEPPS, SFRP1, TBL2, LMNA, UBQLN1, RORA, ATP7A, KCNK3, SIRT2]
GO:0051965;positive regulation of synapse assembly;7.0;0.8259837884571596;0.7639112594857803;9.437469015729413;224.643362448917;5.602686357784832;0.007518611175264769;0.6374410061458773;[OXTR, ADNP]
GO:0010592;positive regulation of lamellipodium assembly;9.0;1.0;0.896240625180289;9.628524252492122;310.04759849733875;6.8867018697843045;0.010377014096983099;0.7484268790654467;[NCKAP1, ARPC2, ATP7A]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[OXTR, AHCYL1, SUCNR1, DGKA, DEFB1, IQGAP2, CRHR1, RIC8A, HEBP1, ABR, GNG2, GNAT2, RGS1, TBXA2R, ADORA3, NPPA, OR56B1, ECT2, CCR2, SPHK2, CCL20, SPHK1, TSHR, SFRP1, GAL, GNAQ, NMUR1, CALM1, DAGLB, CALM2, ARHGEF5]
GO:0032482;Rab protein signal transduction;8.0;1.0;0.875;9.628524252492122;29.60642063139588;5.500407508664414;9.9090025448413E-4;0.6562910957882058;[RAB21, RAB3B, RAB43, RAB18, RAB27B, RAB8B]
GO:0042220;response to cocaine;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;106.24722930474235;6.343086423195323;0.0035559991485312878;0.647506047256038;[EFTUD2, OXTR]
GO:1904706;negative regulation of vascular smooth muscle cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;80.8833163751231;6.8867018697843045;0.0027070918088165762;0.7031056191423581;[CDKN1A]
GO:0006897;endocytosis;5.0;0.6324783794010864;0.6064802015614634;8.088079211544972;26.35802846831835;3.582668236575797;8.821794921490709E-4;0.47345883209051776;[COLEC12, CD163L1, TFRC, AMBP, FNBP1, WIPF2, ITGB3, ITGB2, CLTA, FNBP1L, RABEPK, LRP8, TM9SF4, UNC13D, RUFY1, KIAA1109, SYNJ1, SNX17, CD9, DOCK2]
GO:0043434;response to peptide hormone;6.0;0.6696747006330769;0.657957662906683;8.712233520617966;71.32532737153224;4.149452513989832;0.0023871945184980284;0.5353235071248601;[ERRFI1, BTG2, OXTR, ABCC2, IGFBP5, MAX, CRHR1, TSHR, GAL, SP1, NPPA, SCAP, CYC1, RAB8B]
GO:0045736;negative regulation of cyclin-dependent protein serine/threonine kinase activity;12.0;0.8933024483968273;0.8947715367885583;9.585964638073326;2927.1185870500644;6.375876246018314;0.09796802487286638;0.7741829203200885;[CDKN1A]
GO:0006654;phosphatidic acid biosynthetic process;8.0;1.0;0.875;9.628524252492122;659.6112576846374;6.139487467954083;0.022076595183113425;0.6889736746265369;[PLA2G12A, DGKA]
GO:0032914;positive regulation of transforming growth factor beta1 production;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;85.62186638127122;7.9853141584524145;0.0028656868131042177;0.7592887026755414;[THBS1]
GO:0071560;cellular response to transforming growth factor beta stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;5.788089581116195;0.003262744749111514;0.6191234829421188;[SFRP1, LIMS1]
GO:0033209;tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;30.19135422731818;5.395046993006588;0.00101047745553359;0.6268223193749;[KARS, LIMS1]
GO:0070474;positive regulation of uterine smooth muscle contraction;9.0;1.0;0.896240625180289;9.628524252492122;87.9006140514566;7.697632086000634;0.0029419544468855647;0.7898978880348613;[OXTR]
GO:0051056;regulation of small GTPase mediated signal transduction;7.0;0.6799073451904818;0.6908730378524415;8.647694999480395;45.070113835906206;4.018171853803189;0.001508456149618737;0.5564088607247961;[BCR, ABR, FLCN, ARHGAP21, DEPDC1B, RHOT1, ALS2, NUP62, ECT2, A2M, ARHGAP25, ARHGEF5]
GO:0002605;negative regulation of dendritic cell antigen processing and presentation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;55.710237364246;9.083926447120524;0.0018645715086227877;0.7876727335416686;[THBS1]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[CD4, SFRP1, OXTR, ITGA2, EZH2]
GO:0030178;negative regulation of Wnt signaling pathway;7.0;0.6835726970475526;0.6927057137809769;8.781226392104918;188.91844949246428;4.7018998124466425;0.006322930488946581;0.591374740326424;[TLE4, SFRP1, HDAC1, DVL3, TAX1BP3, APCDD1, DACT1]
GO:2000601;positive regulation of Arp2/3 complex-mediated actin nucleation;13.0;1.0;0.9625549647676366;9.628524252492122;774.2616619260014;7.8311634786251565;0.025913841034406984;0.8630410292508717;[NCKAP1]
GO:0016567;protein ubiquitination;9.0;0.6913464685778243;0.7419138594692012;8.996001693748612;153.79381005389072;3.300101264790787;0.005147340417060716;0.5650079573320931;[HIST1H2BO, HIST1H2BJ, RNF38, CCNF, NEDD8, DTX2, ANAPC11, UBE2L3, VCPIP1, TRIM9, NPEPPS, HERC1, TRIM24, TRIM69, RFFL, SKP2, C18orf25, UBE2I, UBE2B, FBXO18, KLHL25, SYVN1, ZFP91, FBXL15, LNPEP, FBXL16, DDB1, ITCH, KCTD10, UBE2T, TSPAN17, FBXL3, ANAPC5]
GO:0036155;acylglycerol acyl-chain remodeling;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.59385656069774;7.697632086000634;0.0028647493496168257;0.7445766281117727;[MGLL]
GO:0014003;oligodendrocyte development;5.0;1.0;0.7902410118609202;9.628524252492122;34.09911675737102;6.558197802812269;0.001141266750656509;0.6256275524841266;[CD9]
GO:1904031;positive regulation of cyclin-dependent protein kinase activity;11.0;0.8653626801206646;0.8651102923899945;9.580896203502867;1273.8390836462854;6.063501560976162;0.04263424774889523;0.7425167041396421;[CDKN1A]
GO:0032230;positive regulation of synaptic transmission, GABAergic;8.0;1.0;0.875;9.628524252492122;135.4246808583232;7.212124270218933;0.0045325421940280546;0.7438283705770736;[OXTR]
GO:0036151;phosphatidylcholine acyl-chain remodeling;8.0;1.0;0.875;9.628524252492122;185.56639978848355;6.481236761676141;0.0062107404020032226;0.7064507494004503;[PLA2G12A]
GO:0090630;activation of GTPase activity;7.0;1.0;0.8509193652572005;9.628524252492122;49.337455126924546;5.2552850506314295;0.0016512802222712962;0.6196748871422394;[RABGAP1, TAX1BP3, EVI5L, ECT2, EPHA1, TBC1D22A]
GO:0030050;vesicle transport along actin filament;7.0;0.9326813400603323;0.8172600352873667;9.574457031221845;136.86115064074093;7.697632086000634;0.004580619544906703;0.7445766281117727;[FNBP1L]
GO:0036152;phosphatidylethanolamine acyl-chain remodeling;8.0;1.0;0.875;9.628524252492122;185.56639978848355;6.518977089658987;0.0062107404020032226;0.7083807915285978;[PLA2G12A]
GO:1902894;negative regulation of pri-miRNA transcription by RNA polymerase II;12.0;1.0;0.9481203125901445;9.628524252492122;2093.976898733065;7.292166977892469;0.07008352234373612;0.8210420709600095;[YY1, NFIB]
GO:0036150;phosphatidylserine acyl-chain remodeling;8.0;1.0;0.875;9.628524252492122;193.21857951287598;6.7325511899570465;0.006466851970863995;0.719302980950052;[PLA2G12A]
GO:0006986;response to unfolded protein;5.0;0.8653626801206646;0.7229223519212526;9.34084218004034;23.958124258549983;5.75172193694532;8.018568580216882E-4;0.5843843391987277;[HERPUD2, HSPB3, THBS1]
GO:0006978;DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator;8.0;1.0;0.875;9.628524252492122;145.46952913610525;7.004484905440688;0.004868734226108882;0.7332096838060964;[CDKN1A]
GO:0000086;G2/M transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;43.44612409677276;4.981283082083729;0.0014541026745458175;0.5449840603320351;[CDKN1A, CEP70, FBXL15, SKP2, CLASP1, PAFAH1B1]
GO:0006977;DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest;11.0;1.0;0.9324289523296623;9.628524252492122;888.119660647831;5.75172193694532;0.0297245657860804;0.7265722796674696;[CNOT6, BTG2, CDKN1A, TFDP2, CNOT1, CASP2, EP300, CNOT10, CNOT8, E2F7, E2F8]
GO:0072201;negative regulation of mesenchymal cell proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;64.27901505963113;7.697632086000634;0.002151360786688069;0.7167775754447168;[NFIB, LMNA]
GO:0001967;suckling behavior;3.0;1.0;0.6981203125901445;9.628524252492122;23.343114208171034;7.212124270218933;7.812730251086156E-4;0.5669486831672182;[OXTR, DERL2]
GO:0000082;G1/S transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;42.752976916212816;5.142344639450834;0.0014309036622044387;0.5532207558659172;[POLE4, CDKN1A, MAX, GMNN, SKP2, MCM2]
GO:2001027;negative regulation of endothelial cell chemotaxis;10.0;0.9326813400603323;0.8815816818910864;9.593432932680852;484.3135532944439;8.390779266560578;0.016209538774865105;0.8443458537639685;[THBS1]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[SFRP1, ABCC2, CCL20, CIB1, RORA, THBS1]
GO:0036148;phosphatidylglycerol acyl-chain remodeling;8.0;1.0;0.875;9.628524252492122;148.59002936247938;6.8867018697843045;0.004973174560417748;0.7271862538851576;[PLA2G12A]
GO:0036149;phosphatidylinositol acyl-chain remodeling;8.0;1.0;0.875;9.628524252492122;149.40095957869912;6.943860283624253;0.005000315664964811;0.7301093378270707;[PLA2G12A]
GO:0035176;social behavior;3.0;1.0;0.6981203125901445;9.628524252492122;22.58175877758554;5.8067817141283475;7.557911440223213E-4;0.49507939949363344;[TBX1, OXTR]
GO:0060574;intestinal epithelial cell maturation;6.0;1.0;0.8231203125901445;9.628524252492122;41.35061092186203;8.390779266560578;0.0013839677344209735;0.7522251544931926;[CDKN1A]
GO:0090400;stress-induced premature senescence;5.0;0.9326813400603323;0.7565816818910864;9.541512875502493;55.82928668984125;7.697632086000634;0.0018685559824130236;0.6838982747154925;[CDKN1A, ARNTL]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[NCKAP1, CIITA, OXTR, CDKN1A, MAML1, WIPF2, ITGB3, ITGB2, IL5RA, CIB1, PKD2L1, RORA, TIAL1, GNAT2, ADORA3, NUP62, NPPA, CASP2, EP300, CCR2, DACT1, TLE4, IFNAR2, SEMA6B, IL4R, CAMLG, CSNK2A1, ITGA2, ROM1, FLT3LG, SENP2, GFRA2, YWHAZ, RUNX2, SIRT2, BCR, DDB1, SFRP1, KARS, SLC9A6, CD8B, IL23A, ELMO1, PSME2, TAX1BP3, LCP1, EPHA1, DAGLB, CD151, DIABLO, NOTCH2NL, NEDD9, DTX2, APCDD1, LRP8, AKAP2, CRHR1, SGPL1, GNG2, POLR2B, BAG3, MKNK2, TSPAN7, TSPAN4, IL21R, DVL3, POLR2G, NCAM1, NCKAP1L, TSPAN2, MARK2, ATP6V1F, FAM83A, BBS2, MAP3K3, CREBBP, UBE2B, BTN2A1, CCL20, IFT122, G0S2, TSHR, SETX, VIL1, ITCH, CD4, COL1A2, ARPC2, PTPRA, GNAQ, TSPAN17, SDC1, CD9, CCM2, CALM1, LIMS1]
GO:0060455;negative regulation of gastric acid secretion;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;130.62186792824087;7.9853141584524145;0.004371796367509212;0.7592887026755414;[OXTR]
GO:0006633;fatty acid biosynthetic process;8.0;0.6493065804076676;0.6996532902038338;8.912904216080118;359.8485513982277;5.076593261888053;0.01204380717262807;0.6346172154986847;[ELOVL5, HSD17B8, FADS1, MGLL]
GO:0070371;ERK1 and ERK2 cascade;10.0;1.0;0.9152410118609203;9.628524252492122;233.3964595037646;6.481236761676141;0.007811569456414605;0.7466917612613706;[OXTR, KARS]
GO:0001975;response to amphetamine;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;70.50276562849314;6.558197802812269;0.0023596641172160164;0.6585068532133508;[OXTR]
GO:0032695;negative regulation of interleukin-12 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;7.004484905440688;0.002184000309729388;0.6813299963962409;[THBS1]
GO:0030951;establishment or maintenance of microtubule cytoskeleton polarity;6.0;0.9326813400603323;0.7894609826203107;9.533214072687796;65.29771360028688;8.390779266560578;0.002185455710074652;0.7522251544931926;[LMNA]
GO:0045807;positive regulation of endocytosis;7.0;0.6873818243518346;0.6946102774331178;8.89763674394933;124.48668476360231;4.886724499458715;0.0041664573082951335;0.6008266834154484;[RAB21, BCR, ABR, CD151, SYNJ1, ITGA2, SIRPG, PTX3, NCKAP1L, DOCK2, C2]
GO:1903243;negative regulation of cardiac muscle hypertrophy in response to stress;9.0;1.0;0.896240625180289;9.628524252492122;308.04883931045805;7.9853141584524145;0.010310117425764685;0.8046099625986299;[ERRFI1, LMNA]
GO:0015031;protein transport;7.0;0.4793097133439409;0.590574221929171;6.989466922876863;54.45792783373929;2.578890050578526;0.0018226578356421344;0.4828039223744382;[RAB3B, TRAM1, AHCTF1, AHCYL1, SYS1, SFT2D3, TFRC, CLTA, LYST, RAB43, EIF4ENIF1, NUP62, TMED2, TMED1, EVI5L, TNPO2, SNAP29, TBC1D22A, RAB8B, VPS18, GSTK1, TMED9, RPS9, PDCD6IP, SSR2, VPS33B, COG3, RHBDF2, FGG, COG1, SENP2, BCR, RUFY1, GAL, ACOX2, AGPS, CHMP6, SLU7, VAMP5, KPNB1, ACOT4, PAFAH1B1, EXOC1, RABGAP1, SUCNR1, GOSR1, HSD17B4, ZDHHC24, DERL2, RRBP1, VPS26B, TRAK1, NAPG, ARNTL, RAB21, AP3M1, SNX25, VPS8, LMNA, VPS11, ECT2, ATP6V1F, RPL19, VPS16, PEX16, BBS2, PEX19, SYVN1, NUP153, RAB27B, ARCN1, CENPF, PAN3, SNX17, VPS41, RAB18, SEC24C]
GO:0043068;positive regulation of programmed cell death;6.0;0.544374901031353;0.595307763105821;7.549082710812286;59.39447578849882;3.3868329606151195;0.001987879653083215;0.4963231076998412;[HRK, CDKN1A, DIABLO, THBS1, BBC3, ABR, FLCN, RPS6KA2, TP53INP1, CASP2, SUDS3, ECT2, RBM5, TFAP2A, FBXO18, ATPIF1, G0S2, YWHAZ, SIRT2, NLRP12, SFRP1, GAL, TFDP2, PTRH2, PDCD1, SERINC3, ARHGEF5]
GO:0051491;positive regulation of filopodium assembly;9.0;1.0;0.896240625180289;9.628524252492122;200.30665838708023;6.409777797693995;0.006704083591926775;0.7240369598395108;[DOCK11, FNBP1L]
GO:0042771;intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;8.0;1.0;0.875;9.628524252492122;164.97679920792456;6.409777797693995;0.005521625000009403;0.7027963346592216;[CDKN1A, EP300]
GO:0060406;positive regulation of penile erection;5.0;1.0;0.7902410118609202;9.628524252492122;118.0711512965144;8.16763571524637;0.003951735176756968;0.7079342821725234;[OXTR]
GO:0090051;negative regulation of cell migration involved in sprouting angiogenesis;11.0;1.0;0.9324289523296623;9.628524252492122;662.774530299232;7.069023426578259;0.02218246707076338;0.7939391391080821;[TBXA2R, THBS1]
GO:0042535;positive regulation of tumor necrosis factor biosynthetic process;8.0;1.0;0.875;9.628524252492122;857.3444905607055;7.379178354882098;0.028694548539119222;0.7523715242355574;[THBS1, CCR2]
GO:0045921;positive regulation of exocytosis;8.0;0.6913464685778243;0.7206732342889122;8.870838550794605;171.96353606350112;5.407625775213448;0.00575546479491061;0.6515462336247315;[FGA, PDCD6IP, IL4R, NPPA, ITGB2, FGG, SDC1, RAB27B, CLASP1, UNC13D]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[BECN1, CREBBP, ITGA2, ITPR2, ARNT, RORA, THBS1, TM9SF4, SIRT2, NPEPPS, ALKBH5, SFRP1, TBL2, NPPA, LMNA, UBQLN1, EP300, SCAP, ATP7A, KCNK3]
GO:0030308;negative regulation of cell growth;6.0;0.6913464685778243;0.6687935468790567;8.673012807464685;80.89021177018715;4.623782033182691;0.0027073225914839173;0.5595807407949613;[SEMA6B, FLCN, SERTAD3, SFRP1, CDKN1A, GAL, NPPA]
GO:0050830;defense response to Gram-positive bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.334422371190153;0.0023911797157970473;0.6237219733958743;[HIST1H2BJ, DEFB1, RNASE3]
GO:1902043;positive regulation of extrinsic apoptotic signaling pathway via death domain receptors;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;424.7653704329427;6.943860283624253;0.014216514684375884;0.7703503496879909;[SFRP1, THBS1]
GO:0000902;cell morphogenesis;4.0;0.6260725219892441;0.563036260994622;7.923776160253697;43.26261951924051;4.420487353008457;0.0014479609414792109;0.47606392880653703;[NCKAP1, PARVG, VSIG1, ITGB3, LST1, NCKAP1L, THOC2, ECT2, EPHA1]
GO:0060510;Type II pneumocyte differentiation;7.0;1.0;0.8509193652572005;9.628524252492122;48.44599961187319;8.16763571524637;0.0016214440084404039;0.7686126355688037;[NFIB]
GO:0006334;nucleosome assembly;7.0;0.8653626801206646;0.7836007053175329;9.474373572664863;104.51542930890014;4.99795013456894;0.0034980373611892576;0.6065147675675062;[HIST1H2BO, CHAF1A, HIST1H2BJ, H3F3A, OIP5, TSPYL6, CENPP, MCM2]
GO:0061844;antimicrobial humoral immune response mediated by antimicrobial peptide;6.0;1.0;0.8231203125901445;9.628524252492122;44.28377145688295;5.682729065458369;0.0014821379778550245;0.6137353412716126;[HIST1H2BJ, DEFB1, RNASE3]
GO:0030890;positive regulation of B cell proliferation;9.0;1.0;0.896240625180289;9.628524252492122;506.1565706318756;6.063501560976162;0.016940604907709607;0.706328376990269;[CDKN1A, TFRC, NCKAP1L]
GO:0050727;regulation of inflammatory response;6.0;0.5272636092234699;0.5867521172018795;7.400047131651798;31.586589572713706;3.8007227183825356;0.00105717472691369;0.517489449159909;[CUEDC2, SUCNR1, ITGA2, OTUD7B, RORA, C2, BCR, ABR, NLRP12, KARS, NLRP7, IL23A, NPPA, A2M, MGLL, C1QC, CCR2]
GO:0010701;positive regulation of norepinephrine secretion;9.0;1.0;0.896240625180289;9.628524252492122;256.4377692991565;8.390779266560578;0.008582741359433842;0.8253454670833372;[OXTR]
GO:0070317;negative regulation of G0 to G1 transition;7.0;1.0;0.8509193652572005;9.628524252492122;83.03241800612349;6.139487467954083;0.002779020306340262;0.6648930398837374;[TFDP2, MAX, EZH2]
GO:0031623;receptor internalization;7.0;0.7248374789738407;0.7133381047441208;9.201080237665183;64.84818556283533;5.682729065458369;0.0021704104112101165;0.6415343939386686;[SYNJ1, TFRC, ITGB2, CD9]
GO:0071404;cellular response to low-density lipoprotein particle stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;56.74958382123113;7.004484905440688;0.0018993574991869968;0.6813299963962409;[ITGB2, CD9]
GO:0090399;replicative senescence;4.0;1.0;0.75;9.628524252492122;26.138269705024182;7.212124270218933;8.748243641116619E-4;0.6188283705770736;[CDKN1A]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[CDKN1C, BECN1, BTG2, CDKN1A, LST1, SIRPG, CIB1, COMT, THBS1, FLCN, ADORA3, RPS6KA2, FNTB, NUP62, TP53INP1, LMNA, TRIM24, RBM5, E2F7, TFAP2A, KLF13, IGFBP5, ATPIF1, IDH2, IFT122, EMP3, SIRT2, PER2, ITCH, SFRP1, GAL, KARS, NFIB, CD9, TAX1BP3, CNOT8]
GO:0002062;chondrocyte differentiation;4.0;0.8933024483968273;0.6966512241984136;9.446202695698167;21.066225782797595;6.039404009397101;7.050676185779127E-4;0.5588554019015759;[NFIB, RUNX2]
GO:0051271;negative regulation of cellular component movement;5.0;0.5470854108181258;0.5637837172699831;7.364160372318274;52.38761662992485;4.128099389519264;0.001753366382809582;0.5013522066171892;[SEMA6B, IGFBP5, IDH2, THBS1, BCR, ABR, FLCN, SFRP1, RRAS, TBXA2R, ADORA3, TP53INP1, CD9, EPHA1, CLASP1]
GO:0006661;phosphatidylinositol biosynthetic process;8.0;0.7508913569872202;0.7504456784936101;9.237657943805111;661.808482261977;4.917261223318797;0.022150134312343243;0.6264689676365554;[RUFY1, DPM3, SYNJ1]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[CIITA, ONECUT2, ELL, MAML1, GFI1, ARID4A, RORA, DDX41, HOXC13, AATF, IKZF2, ELK1, YY1, FLCN, NIPBL, DPF2, EP300, SOX8, IER5, ZNF564, IER2, ZNF485, KLF13, PEG3, NCOA6, ARNT, FLT3LG, SENP2, SAFB, TMEM173, MED6, RUNX2, SIRT2, CREB3, GAL, TFDP2, IL23A, RFX4, MTF2, TFEC, HOXB4, HDAC3, ZNF350, HDAC1, WBP2, MAX, RLF, SUPT6H, ARNTL, RXRA, SCAP, E2F7, E2F8, TBX1, TFAP2A, ZNF462, DR1, CREBBP, NFYC, ATAD2, PBX3, ERLIN2, GRHL1, USF2, FLI1, SETX, CDK9, TFCP2, COPS5, SP1, NFIB, NFIC, SP3, TAF7, CAMK1]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[ERN1, IGFBP5, ITGA2, SKP2, THBS1]
GO:0034329;cell junction assembly;4.0;0.7140352122741334;0.6070176061370667;8.529911963824013;35.00514165935835;4.7018998124466425;0.0011715905887565515;0.49045537506922354;[UGT8, FLCN, PDCD6IP, CD151, ITGA2, CD9, PKP4, ECT2, LIMS1]
GO:0007084;mitotic nuclear envelope reassembly;6.0;1.0;0.8231203125901445;9.628524252492122;35.641415366952565;7.8311634786251565;0.0011928860971405699;0.7236063770733796;[LMNA]
GO:2000791;negative regulation of mesenchymal cell proliferation involved in lung development;7.0;1.0;0.8509193652572005;9.628524252492122;166.62551907350917;9.083926447120524;0.005576806170158974;0.8154717862087246;[NFIB]
GO:0009267;cellular response to starvation;6.0;0.6369964171292115;0.6416185211547503;8.460919092337061;112.76702064936369;4.807260328104469;0.0037742106974044997;0.5689638293298743;[BECN1, GABARAPL1, SFRP1, CDKN1A, TBL2, MAX, CLEC16A, COMT, FADS1]
GO:0043536;positive regulation of blood vessel endothelial cell migration;10.0;0.9326813400603323;0.8815816818910864;9.584072489921288;355.43002650478036;5.8067817141283475;0.011895923120858621;0.7122000987644093;[MAP3K3, SP1, CIB1, THBS1]
GO:0010804;negative regulation of tumor necrosis factor-mediated signaling pathway;8.0;1.0;0.875;9.628524252492122;306.2706419112467;6.7325511899570465;0.010250602759086841;0.719302980950052;[HIST1H2BJ, RFFL]
GO:0019731;antibacterial humoral response;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;115.72816977122699;6.221725566191056;0.0038733176936520722;0.6690987000520388;[FGA, HIST1H2BJ, DEFB1, RNASE3]
GO:0010243;response to organonitrogen compound;4.0;0.45240132074476547;0.47620066037238273;6.234015858980763;25.42702214820504;3.12938525411714;8.510195484661687E-4;0.4100369074268474;[ERRFI1, BTG2, OXTR, CDKN1A, MAX, ITGB2, ITPR2, DERL2, CRHR1, EFTUD2, GNG2, NPPA, UBQLN1, SCAP, CYC1, ATP7A, RAB8B, ABCC2, IGFBP5, ITGA2, EDEM1, SYVN1, ERLIN2, TSHR, SIRT2, SFRP1, GAL, COL1A2, SP1, TIMELESS, SDC1, CD9, MAN1B1, EZH2]
GO:0010001;glial cell differentiation;4.0;0.7192862368539868;0.6096431184269935;8.404748820870006;21.066225782797595;5.528578385631111;7.050676185779127E-4;0.5327317557463623;[NFIB, NAB1, SOX8, TSPAN2]
GO:0030511;positive regulation of transforming growth factor beta receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;345.4564576873422;6.518977089658987;0.011562116748168153;0.7083807915285978;[CDKN1C, FLCN, THBS1]
GO:0016601;Rac protein signal transduction;8.0;1.0;0.875;9.628524252492122;29.60642063139588;6.7325511899570465;9.9090025448413E-4;0.719302980950052;[NCKAP1, ALS2, ELMO1]
GO:0006366;transcription by RNA polymerase II;10.0;0.6039883530135606;0.7172351883677006;8.613793447804714;583.8786478812184;3.2909128387363804;0.01954189288791682;0.5835384474769965;[ONECUT2, ELL, WBP2, MAX, INTS10, ARID4A, HOXC13, ELK1, SUPT6H, GTF2E2, ARNTL, POLR2B, TRIM24, ZNF768, HIVEP1, EP300, POLR2G, IER2, GTF2I, TFAP2A, TBP, KLF13, NFYC, INTS3, PBX3, ARNT, GRHL1, USF2, FLI1, CDK9, CREB3, GFI1B, TFCP2, COPS5, TFDP2, SP1, NFIB, NFIC, RFX4, TFEC, INTS4, LCOR, TAF7]
GO:0006367;transcription initiation from RNA polymerase II promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;4.629579150867016;0.015969835568764485;0.6329975182530758;[CREBBP, CDKN1A, TBP, MAML1, RORA, MED6, RUNX2, GTF2E2, CDK9, RXRA, POLR2B, NPPA, TAF7, POLR2G, GTF2I]
GO:0072384;organelle transport along microtubule;7.0;0.6835726970475526;0.6927057137809769;8.935377071932177;89.05634386756805;5.514393750639154;0.0029806356837415084;0.6329257181104212;[AP3M1, ARHGAP21, SPAST, RHOT1, TRAK1, PAFAH1B1]
GO:0009749;response to glucose;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;32.95598622603122;4.917261223318797;0.001103007200523252;0.6023883328937558;[ERN1, THBS1]
GO:0051684;maintenance of Golgi location;6.0;1.0;0.8231203125901445;9.628524252492122;40.05853332144524;8.67846133901236;0.001340723059929369;0.7669372290569613;[ARHGAP21]
GO:0071850;mitotic cell cycle arrest;7.0;0.8653626801206646;0.7836007053175329;9.420884887713877;120.3495477317274;7.069023426578259;0.00402799105501988;0.7124295520356204;[CDKN1A]
GO:0051683;establishment of Golgi localization;5.0;1.0;0.7902410118609202;9.628524252492122;43.319684629467496;7.697632086000634;0.0014498708593632431;0.6838982747154925;[ARHGAP21, YWHAZ]
GO:0006914;autophagy;4.0;0.6729672293956388;0.5864836146978194;8.39638057119949;37.75222312160081;4.39717627414001;0.001263532933085;0.4748717991491287;[VPS18, BECN1, GABARAPL1, CALCOCO2, CLEC16A, PGA3, FNBP1L, DYNLL2, PGA5, SIRT2, VPS41, VPS11, UBQLN1, C6orf106, CHMP6, MARK2]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[VIL1, CSNK2A1, RFFL, THBS1]
GO:0043032;positive regulation of macrophage activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;126.59742726208806;6.641579411751319;0.004237101960174532;0.6905700452391912;[IL4R, KARS, ITGB2, THBS1]
GO:0016055;Wnt signaling pathway;7.0;0.5916390046238794;0.6467388675691402;7.647522783625538;28.581916314885376;4.0633408221711;9.566110170045473E-4;0.558718803867703;[TLE4, CSNK2A1, UBE2B, SENP2, APCDD1, DDB1, SFRP1, GNG2, GNAT2, DVL3, SDC1, TAX1BP3, CALM1, MARK2, DACT1]
GO:0030100;regulation of endocytosis;6.0;0.5902001590945054;0.6182203921373972;8.152617732682543;44.90533409728707;4.321752512322768;0.0015029411200592913;0.5441349370523758;[CD151, ITGA2, SIRPG, C2, RAB21, BCR, RUFY1, ABR, ATXN2, SYNJ1, SNX17, PTX3, NCKAP1L, DOCK2]
GO:0032402;melanosome transport;8.0;1.0;0.875;9.628524252492122;154.03816563912218;6.686031174322154;0.005155518778592664;0.7169239451870815;[BBS2, RAB27B]
GO:2000795;negative regulation of epithelial cell proliferation involved in lung morphogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;189.345871517076;9.777073627680469;0.0063372359194554875;0.8509193652572005;[NFIB]
GO:0060271;cilium assembly;6.0;0.8653626801206646;0.7558016526504768;9.405380701177911;137.68250629835126;4.347727998726029;0.00460810957959482;0.5454633246350222;[BBS2, SPAG16, ONECUT2, RFX4, TMEM107, IFT122, CCDC65, FNBP1L, SNAP29, DYNLL2, CLUAP1]
GO:0007342;fusion of sperm to egg plasma membrane involved in single fertilization;6.0;1.0;0.8231203125901445;9.628524252492122;41.84633322739465;7.004484905440688;0.0014005591138660403;0.6813299963962409;[CD9]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[NAB1, GFI1, GMNN, ARID4A, CASC3, IKZF2, YY1, EIF4ENIF1, SAP130, DPF2, TRIM24, WWC3, EP300, SOX8, ZNF564, TLE4, RPS9, IGFBP5, ZNF282, SND1, RUNX2, ERN1, OLFM1, EID1, ILF3, SFRP1, ZNF93, HOXB4, TIMELESS, ADNP, MAX, FOXG1, SUPT6H, GLG1, NLRP7, BAG3, TPR, HIVEP1, SUDS3, A2M, BBS2, TFAP2A, DR1, CREBBP, UBE2I, H3F3A, CNOT10, CDK9, CNOT6, PAN3, CNOT1, PKIA, SP3, ZNF658, CNOT8, EZH2, CDKN1C, USP36, CIITA, BTG2, CDKN1A, OTUD7B, SMG5, FLCN, NIPBL, LRRFIP1, DACT1, UPF2, ZNF485, UPF1, TSC22D4, PEG3, SIRT2, TFDP2, PTRH2, MTF2, LCOR, EIF4E2, DCP2, HDAC3, ZNF350, HDAC1, LRP8, THBS1, ARNTL, RXRA, U2AF2, TP53INP1, POLR2G, E2F7, ZNF189, RPL19, E2F8, IRX1, NFYC, PER2, CENPF, GFI1B, HIST3H2A, NFIB, NFIC, TAF7, LIMS1]
GO:0050482;arachidonic acid secretion;12.0;1.0;0.9481203125901445;9.628524252492122;224.85573033724626;6.599019797332524;0.007525718937368459;0.7855944919115336;[PLA2G12A]
GO:0010628;positive regulation of gene expression;6.0;0.4705935272257725;0.5584170762030307;6.666693530613812;58.797024432214236;2.2471302570788807;0.001967883493859682;0.43803865843940215;[MAML1, GFI1, ARID4A, RORA, IKZF2, ELK1, YY1, ZXDC, DPF2, TRIM24, EP300, SOX8, IER5, ZNF564, IER2, RPS9, FLT3LG, MED6, RUNX2, ERN1, OLFM1, ILF3, SFRP1, KARS, IL23A, RFX4, HOXB4, MAX, RLF, SUPT6H, DVL3, SCAP, TFAP2A, DR1, CREBBP, PBX3, ERLIN2, FLI1, SETX, CDK9, TFCP2, COPS5, SP1, SP3, CDKN1C, CIITA, ONECUT2, ELL, DDX41, HOXC13, AATF, FLCN, NIPBL, LBH, NUP62, TMED2, ZNF485, TBP, KLF13, PEG3, NCOA6, ITGA2, ARNT, SENP2, SAFB, TMEM173, SIRT2, CREB3, GAL, TFDP2, MTF2, TFEC, POLR1E, HDAC3, ZNF350, HDAC1, WBP2, THBS1, ARNTL, SERTAD3, RXRA, U2AF2, TP53INP2, TP53INP1, LMNA, POLR2G, GPBP1L1, E2F7, E2F8, TBX1, ZNF462, NFYC, ATAD2, GRHL1, USF2, CD4, NFIB, NFIC, CAMK4, TAF7, CAMK1, LIMS1]
GO:0010748;negative regulation of plasma membrane long-chain fatty acid transport;9.0;1.0;0.896240625180289;9.628524252492122;652.3932031735304;8.390779266560578;0.02183501339445399;0.8253454670833372;[THBS1]
GO:0016042;lipid catabolic process;4.0;0.5127202928476964;0.5063601464238482;6.883086519318291;43.14795622097559;4.114113147544524;0.0014441232640765526;0.4603959376912539;[HSD3B7, PLA2G12A, SPHK1, HSD17B4, ETFB, SIRT2, SGPL1, ACOX2, CPT2, SNX17, DAGLB, HRASLS, MGLL, PAFAH1B1]
GO:0032870;cellular response to hormone stimulus;5.0;0.6039883530135606;0.5922351883677006;7.932074963068391;80.94247679971589;3.9540277321974506;0.0027090718549867714;0.49245017396659174;[ERRFI1, OXTR, ABCC2, MAX, ITGA2, ELK1, CRHR1, TSHR, UBE2L3, SFRP1, GNG2, SP1, RAB8B]
GO:0055015;ventricular cardiac muscle cell development;7.0;1.0;0.8509193652572005;9.628524252492122;69.56390858866273;7.379178354882098;0.002328241417009372;0.728290889492758;[LMNA]
GO:0019433;triglyceride catabolic process;8.0;1.0;0.875;9.628524252492122;492.4915826757067;6.518977089658987;0.01648325005850736;0.7083807915285978;[MGLL]
GO:0030334;regulation of cell migration;6.0;0.4770562410916853;0.5616484331359872;7.1128459440373675;36.74126027361157;3.1319826581748256;0.0012296969163702938;0.48329005138129355;[CD151, ONECUT2, DOCK8, ITGB3, CIB1, THBS1, ABR, FLCN, NIPBL, RRAS, TBXA2R, ADORA3, TP53INP1, LMNA, NCKAP1L, ATP7A, RFFL, CLASP1, CCR2, SEMA6B, MAP3K3, IGFBP5, CCL20, ITGA2, SPHK1, IDH2, PTP4A1, BCR, VIL1, CREB3, SFRP1, KARS, SP1, IL23A, EPHA1]
GO:1900180;regulation of protein localization to nucleus;6.0;0.7369933605727446;0.6916169928765168;9.0094850440859;29.0551629072873;5.014899692882714;9.724501545579579E-4;0.5795825161008517;[FLCN, CDKN1A, HDAC3, BAG3, PKIA, TPR, NUP62, LMNA, OTUD7B, ECT2, TMEM173]
GO:0030335;positive regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.22453031427283;157.26390226612122;3.6656062881777913;0.005263481280523835;0.5383786413027378;[SEMA6B, MAP3K3, CD151, ONECUT2, IGFBP5, CCL20, DOCK8, ITGB3, ITGA2, SPHK1, CIB1, THBS1, PTP4A1, VIL1, CREB3, NIPBL, KARS, SP1, IL23A, NCKAP1L, ATP7A, EPHA1, CLASP1, CCR2]
GO:0045907;positive regulation of vasoconstriction;8.0;0.8933024483968273;0.8216512241984136;9.57973408832269;103.52331479149503;6.280566066213989;0.003464832181136806;0.6961884407023742;[FGA, OXTR, TBXA2R, FGG]
GO:1903588;negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis;10.0;1.0;0.9152410118609203;9.628524252492122;357.96927251473664;8.390779266560578;0.011980909399638815;0.8443458537639685;[THBS1]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[CIITA, BTG2, GFI1, OTUD7B, IKZF2, YY1, FLCN, NIPBL, SAP130, WWC3, EP300, SOX8, LRRFIP1, ZNF564, DACT1, TLE4, PEG3, SIRT2, EID1, MTF2, HOXB4, TIMELESS, LCOR, HDAC3, ZNF350, HDAC1, MAX, FOXG1, LRP8, RXRA, BAG3, TPR, HIVEP1, SUDS3, E2F7, ZNF189, E2F8, IRX1, TFAP2A, DR1, CREBBP, UBE2I, PER2, GFI1B, CNOT1, NFIB, NFIC, PKIA, SP3, TAF7, EZH2]
GO:0032868;response to insulin;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;4.800339885259895;0.0024778305216419678;0.5964089702280253;[ERRFI1, GAL, SP1, MAX, NPPA, SCAP, RAB8B]
GO:0060509;Type I pneumocyte differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;47.34738732320508;8.16763571524637;0.001584674443825551;0.7408135829017477;[NFIB]
GO:0033158;regulation of protein import into nucleus, translocation;9.0;0.8933024483968273;0.8428918493787028;9.517298617381897;190.5797269763205;6.943860283624253;0.006378531951278581;0.7513499630073597;[CDKN1A, TMEM173]
GO:0050829;defense response to Gram-negative bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.407625775213448;0.0023911797157970473;0.627465598881932;[CD4, HIST1H2BJ, IL23A, DEFB1, RNASE3]
GO:0051918;negative regulation of fibrinolysis;9.0;1.0;0.896240625180289;9.628524252492122;332.9628274369728;7.474488534686424;0.011143966187225523;0.7784863164434164;[THBS1]
GO:0061141;lung ciliated cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;47.34738732320508;9.777073627680469;0.001584674443825551;0.8231203125901445;[NFIB]
GO:0007565;female pregnancy;3.0;1.0;0.6981203125901445;9.628524252492122;32.8060485501291;5.299736813202263;0.0010979889214459554;0.4691490996802742;[CLIC5, OXTR, ABCC2, AMBP, IGFBP5, SPHK2, ITGA2, NPPA, LNPEP, COMT, CRHR1]
GO:0007569;cell aging;3.0;0.7980440201809971;0.597142322680643;8.935377071932177;24.751975343904395;5.618190544320798;8.284263394289076E-4;0.485434838299289;[CDKN1A, NUP62, ARNTL, LIMS1]
GO:0021960;anterior commissure morphogenesis;11.0;1.0;0.9324289523296623;9.628524252492122;69.80210411808247;8.16763571524637;0.002336213607016992;0.8501222226412654;[NFIB]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[CD4, OXTR, GNAT2, TBXA2R, ITPR2, CALM1, CALM2, CCR2]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[MAML1, GFI1, ARID4A, RORA, IKZF2, ELK1, YY1, TIAL1, SAP130, ZXDC, DPF2, WWC3, EP300, SOX8, IER5, ZNF564, IER2, GTF2I, TLE4, ZNF282, SSU72, FLT3LG, MED6, RUNX2, EID1, THAP6, SFRP1, ZNF93, IL23A, RFX4, HOXB4, TIMELESS, ADNP, ZNF276, ZNF550, ZNF394, MAX, FOXG1, ZNF20, RLF, SUPT6H, BAG3, TPR, ZNF549, HIVEP1, ZNF548, SCAP, SUDS3, TFAP2A, DR1, CREBBP, UBE2I, PBX3, ERLIN2, FLI1, SOX30, SETX, CDK9, TFCP2, COPS5, CNOT1, SP1, PKIA, SP3, ZNF30, ZNF658, ZNF532, ZNF410, EZH2, CIITA, AHCTF1, BTG2, CDKN1A, ONECUT2, ELL, OTUD7B, DDX41, HOXC13, AATF, CHD1, FLCN, NIPBL, ZMYM2, GATAD1, ZNF768, ZNF525, LRRFIP1, DACT1, ZNF485, TSC22D4, TBP, KLF13, PEG3, NCOA6, BUD31, ZFP91, ARNT, SENP2, SAFB, TMEM173, ZFX, SIRT2, TOX4, CREB3, GAL, ZNF519, TFDP2, MTF2, TFEC, LCOR, HDAC3, ZNF350, HDAC1, WBP2, NEDD8, TRAK1, LRP8, ZNF69, ARNTL, RXRA, E2F7, ZNF189, E2F8, IRX1, TBX1, ZNF462, NFYC, ATAD2, FBXL15, GRHL1, USF2, PER2, GFI1B, NFIB, NFIC, TAF7, CAMK1]
GO:0006900;vesicle budding from membrane;5.0;0.7980440201809971;0.6892630219514189;9.089527751759436;39.266540306241254;6.444869117505266;0.00131421576645793;0.6198319182472036;[FNBP1L]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[BECN1, BTG2, CDKN1A, HDAC3, HDAC1, DOCK8, CIB1, AATF, THBS1, BAG3, NUP62, LMNA, CASP2, SOX8, NCKAP1L, RFFL, SNCB, TBX1, TFAP2A, TSC22D4, FGA, CSNK2A1, UBE2B, SPHK2, SPHK1, FGG, SYVN1, FLT3LG, YWHAZ, SETX, DDB1, VIL1, CREB3, ITCH, SFRP1, CFDP1, SON, COPS5, PTRH2, VDAC2, ADNP, PDCD1, EPHA1, MAD2L1]
GO:0042098;T cell proliferation;6.0;0.7248374789738407;0.6855390520770648;9.081980546124052;51.294476028837884;6.343086423195323;0.0017167799506538708;0.647506047256038;[CD151, IL23A, DOCK8, DOCK2]
